Early Detection and Risk Stratification of Colorectal Cancer Based on miRNA Platform - Trial NCT06351384
Access comprehensive clinical trial information for NCT06351384 through Pure Global AI's free database. This phase not specified trial is sponsored by Sir Run Run Shaw Hospital and is currently Not yet recruiting. The study focuses on Colorectal Cancer. Target enrollment is 600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sir Run Run Shaw Hospital
Timeline & Enrollment
N/A
Apr 01, 2024
Dec 31, 2025
Primary Outcome
Correlation between post-surgery 1 month MRD status and recurrence-free survival (RFS) in colorectal patients
Summary
This is a prospective, observational cohort study to establish the minimal residual disease
 (MRD) model for predicting relapse risk and identifying disease recurrence in patients with
 colorectal adenocarcinoma based on the miRNA platform.
 
 Blood miRNA markers will be evaluated. The study will enroll approximately 600 participants,
 including participants with malignancies or benign diseases, and healthy participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06351384
Device Trial